Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Oncology Reports
Published in: Current Oncology Reports 5/2020

01-05-2020 | Lymphoma | Lymphomas (MR Smith, Section Editor)

Therapy of Peripheral T Cell Lymphoma: Focus on Nodal Subtypes

Authors: Pamela B. Allen, Barbara Pro

Published in: Current Oncology Reports | Issue 5/2020

Login to get access

Abstract

Purpose of Review

Peripheral T cell lymphomas (PTCLs) are a heterogeneous group of non-Hodgkin lymphomas with inferior prognosis compared with their B cell counterparts characterized by frequent relapses, resulting in a median 5-year survival of approximately 30%. Their diverse clinicopathologic features challenge existing treatment paradigms that treat all patients uniformly. Here we review recent advances in the treatment of these diseases.

Recent Findings

While current treatment still relies largely on combination chemotherapy, the introduction of more effective novel and targeted therapies has improved outcomes in certain subtypes. Increasing understanding of the underlying biology of PTCL has prompted further subclassification by genetic and molecular subgroups.

Summary

Overall, the most significant advances in PTCL management have resulted from improved understanding and classification of the biology of PTCL. Ongoing development of subtype-specific targeted therapies will be essential to improve long-term outcomes of patients with these diseases.
Literature
1.
Carson KR, Horwitz SM, Pinter-Brown LC, Rosen ST, Pro B, Hsi ED, et al. A prospective cohort study of patients with peripheral T-cell lymphoma in the United States. Cancer. 2017;123(7):1174–83.PubMedCrossRef
2.
Adams SV, Newcomb PA, Shustov AR. Racial patterns of peripheral T-cell lymphoma incidence and survival in the United States. J Clin Oncol. 2016;34(9):963–71.PubMedPubMedCentralCrossRef
3.
AbouYabis AN, Shenoy PJ, Flowers C, Lechowicz MJ. Response and survival rates in patients with peripheral T-cell lymphoma treated with anthracycline-based regimens: a comprehensive meta-analysis. Blood. 2007;110(11):3452.CrossRef
4.
Schmitz N, Trümper L, Ziepert M, Nickelsen M, Ho AD, Metzner B, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood. 2010;116(18):3418–25.PubMedCrossRef
5.
Mercadal S, Briones J, Xicoy B, et al. Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol. 2008;19(5):958–63.PubMedCrossRef
6.
Ellin F, Landstrom J, Jerkeman M, Relander T. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood. 2014;124(10):1570–7.PubMedCrossRef
7.
Wilhelm M, Smetak M, Reimer P, Geissinger E, Ruediger T, Metzner B, et al. First-line therapy of peripheral T-cell lymphoma: extension and long-term follow-up of a study investigating the role of autologous stem cell transplantation. Blood Cancer J. 2016;6(7):e452.PubMedPubMedCentralCrossRef
8.
• Park SI, Horwitz SM, Foss FM, et al. The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study. Cancer. 2019;125(9):1507–17 One of the largest US-based multicenter prospective analyses assessing the role of autologous transplantation. This study demonstrated a trend toward improvement with autologous transplantation in the overall cohort and specific PTCL subtypes. PubMedCrossRef
9.
Abramson JS, Feldman T, Kroll-Desrosiers AR, Muffly LS, Winer E, Flowers CR, et al. Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy. Ann Oncol. 2014;25(11):2211–7.PubMedPubMedCentralCrossRef
10.
d’Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012;30(25):3093–9.PubMedCrossRef
11.
Piccaluga PP, Fuligni F, De Leo A, et al. Molecular profiling improves classification and prognostication of nodal peripheral T-cell lymphomas: results of a phase III diagnostic accuracy study. J Clin Oncol. 2013;31(24):3019–25.PubMedCrossRef
12.
Watatani Y, Sato Y, Miyoshi H, et al. Molecular heterogeneity in peripheral Tcell lymphoma, not otherwise specified revealed by comprehensive genetic profiling. Leukemia. 2019;33(12):2867–83.
13.
• Heavican TB, Bouska A, Yu J, et al. Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma. Blood. 2019;133(15):1664–76 This analysis helped to define molecular subgroups within PTCL including the subgroups PTCL-GATA3 and PTCL-TBX21 wihtin PTCL, NOS. PubMedPubMedCentralCrossRef
14.
Iqbal J, Wilcox R, Naushad H, Rohr J, Heavican TB, Wang C, et al. Genomic signatures in T-cell lymphoma: how can these improve precision in diagnosis and inform prognosis? Blood Rev. 2016;30(2):89–100.PubMedCrossRef
15.
Attygalle AD, Kyriakou C, Dupuis J, et al. Histologic evolution of angioimmunoblastic T-cell lymphoma in consecutive biopsies: clinical correlation and insights into natural history and disease progression. Am J Surg Pathol. 2007;31(7):1077–88.PubMedCrossRef
16.
Wang M, Zhang S, Chuang SS, et al. Angioimmunoblastic T cell lymphoma: novel molecular insights by mutation profiling. Oncotarget. 2017;8(11):17763–70.PubMedPubMedCentralCrossRef
17.
Piccaluga PP, Tabanelli V, Pileri SA. Molecular genetics of peripheral T-cell lymphomas. Int J Hematol. 2014;99(3):219–26.PubMedCrossRef
18.
Palomero T, Cortes JR, Cooke AR, Belver L, Bhagat G, Ferrando AA. Role of Rhoa G17V in cell migration and transformation in angioimmunoblastic T-cell lymphoma. Blood. 2018;132(Suppl 1):4122.CrossRef
19.
Cortes JR, Ambesi-Impiombato A, Couronne L, et al. RHOA G17V induces T follicular helper cell specification and promotes lymphomagenesis. Cancer Cell. 2018;33(2):259–73 e257.PubMedPubMedCentralCrossRef
20.
Hapgood G, Savage KJ. The biology and management of systemic anaplastic large cell lymphoma. Blood. 2015;126(1):17–25.PubMedCrossRef
21.
22.
• Herrera AF, Crosby-Thompson A, Friedberg JW, et al. Comparison of referring and final pathology for patients with T-cell lymphoma in the National Comprehensive Cancer Network. Cancer. 2014;120(13):1993–9 This article highlights the significant difficulty in diagnosis and classification of PTCL by analyzing concordance between referring and final diagnosis in PTCL in the national Comprehensive Cancer Network. PubMedCrossRef
23.
Reyes F, Lepage E, Ganem G, Molina TJ, Brice P, Coiffier B, et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med. 2005;352(12):1197–205.PubMedCrossRef
24.
Tilly H, Lepage E, Coiffier B, et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood. 2003;102(13):4284–9.PubMedCrossRef
25.
Pfreundschuh M, Trumper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood. 2004;104(3):626–33.PubMedCrossRef
26.
Pfreundschuh M, Trumper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood. 2004;104(3):634–41.PubMedCrossRef
27.
Janikova A, Chloupkova R, Campr V, et al. First-line therapy for T cell lymphomas: a retrospective population-based analysis of 906 T cell lymphoma patients. Ann Hematol. 2019;98(8):1961–72.PubMedCrossRef
28.
Kim YA, Byun JM, Park K, Bae GH, Lee D, Kim DS, et al. Redefining the role of etoposide in first-line treatment of peripheral T-cell lymphoma. Blood Adv. 2017;1(24):2138–46.PubMedPubMedCentralCrossRef
29.
Anselin LSI, Youngihn K. GeoDa: an introduction to spatial data analysis. Geogr Anal. 2005;38(1):5–22.CrossRef
30.
Jia B, Hu S, Yang J, Zhou S, Liu P, Qin Y, et al. Comparison of gemcitabin, cisplatin, and dexamethasone (GDP), CHOP, and CHOPE in the first-line treatment of peripheral T-cell lymphomas. Hematology. 2016;21(9):536–41.PubMedCrossRef
31.
Li L, Duan W, Zhang L, Li X, Fu X, Wang X, et al. The efficacy and safety of gemcitabine, cisplatin, prednisone, thalidomide versus CHOP in patients with newly diagnosed peripheral T-cell lymphoma with analysis of biomarkers. Br J Haematol. 2017;178(5):772–80.PubMedCrossRef
32.
Gleeson M, Peckitt C, To YM, et al. CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial. Lancet Haematol. 2018;5(5):e190–200.PubMedPubMedCentralCrossRef
33.
Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30(18):2190–6.PubMedCrossRef
34.
•• Horwitz S, O'Connor OA, Pro B, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, doubleblind, randomised, phase 3 trial. The Lancet. 2019;393(10168):229–40. This trial demosntrated the superiority of brentuximab vedotin and CHP chemotherpay compared with CHOP in the treatment of newly diagnosed CD30+ PTCL, changing the standard of care in this cohort.
35.
Jagadeesh D, Wei W, Liu X, Tullio K, Majhail NS. Factors impacting the real world use of autologous stem cell transplantation (ASCT) for newly diagnosed peripheral T cell lymphoma (PTCL). Biol Blood Marrow Transplant. 2019;25(3, Supplement):S397.CrossRef
36.
Rodriguez J, Conde E, Gutierrez A, et al. Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from the Gel-Tamo Study Group. Eur J Haematol. 2007;79(1):32–8.PubMedCrossRef
37.
Corradini P, Tarella C, Zallio F, et al. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia. 2006;20(9):1533–8.PubMedCrossRef
38.
Rodriguez J, Conde E, Gutierrez A, et al. Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience. Eur J Haematol. 2007;78(4):290–6.PubMedCrossRef
39.
Fossard G, Broussais F, Coelho I, et al. Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers. Ann Oncol. 2018;29(3):715–23.PubMedCrossRef
40.
Yam C, Landsburg DJ, Nead KT, Lin X, Mato AR, Svoboda J, et al. Autologous stem cell transplantation in first complete remission may not extend progression-free survival in patients with peripheral T cell lymphomas. Am J Hematol. 2016;91(7):672–6.PubMedCrossRef
41.
Tournilhac O, Truemper L, Ziepert M, et al. First-line therapy of T-cell lymphoma: allogeneic or autologous transplantation for consolidation - final results of the AATT study. Hematol Oncol. 2019;37(S2):99–101.CrossRef
42.
Mak V, Hamm J, Chhanabhai M, et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol. 2013;31(16):1970–6.PubMedCrossRef
43.
Maurer MJ, Ellin F, Srour L, Jerkeman M, Bennani NN, Connors JM, et al. International assessment of event-free survival at 24 months and subsequent survival in peripheral T-cell lymphoma. J Clin Oncol. 2017;35(36):4019–26.PubMedPubMedCentralCrossRef
44.
Bellei M, Foss FM, Shustov AR, et al. The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project. Haematologica. 2018;103(7):1191–7.PubMedPubMedCentralCrossRef
45.
Schmitz N, Lenz G, Stelljes M. Allogeneic hematopoietic stem cell transplantation for T-cell lymphomas. Blood. 2018;132(3):245–53.PubMedCrossRef
46.
Epperla N, Ahn KW, Litovich C, Ahmed S, Battiwalla M, Cohen JB, et al. Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis. J Hematol Oncol. 2019;12(1):6.PubMedPubMedCentralCrossRef
47.
Rohlfing S, Dietrich S, Witzens-Harig M, Hegenbart U, Schönland S, Luft T, et al. The impact of stem cell transplantation on the natural course of peripheral T-cell lymphoma: a real-world experience. Ann Hematol. 2018;97(7):1241–50.PubMedCrossRef
48.
• Pro B, Advani R, Brice P, et al. Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood. 2017;130(25):2709–17 This analysis demosntrated significant ongoing responses in patient with anaplastic large cell lymphoma treated with bretnuximab vedotin.
49.
Bartlett NL, Chen R, Fanale MA, et al. Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. J Hematol Oncol. 2014;7:24.PubMedPubMedCentralCrossRef
50.
Horwitz SM, Advani RH, Bartlett NL, Jacobsen ED, Sharman JP, O’Connor OA, et al. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood. 2014;123(20):3095–100.PubMedPubMedCentralCrossRef
51.
O’Connor OA, Horwitz S, Masszi T, van Hoof A, Brown P, Doorduijn J, et al. Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study. J Clin Oncol. 2015;33(23):2492–9.PubMedPubMedCentralCrossRef
52.
Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012;30(6):631–6.PubMedCrossRef
53.
Foss F, Horwitz S, Pro B, et al. Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial. J Hematol Oncol. 2016;9:22.PubMedPubMedCentralCrossRef
54.
O’Connor OA, Pro B, Pinter-Brown L, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011;29(9):1182–9.PubMedPubMedCentralCrossRef
55.
Foss FM, Parker TL, Girardi M, Li A. Effect of leucovorin administration on mucositis and skin reactions in patients with peripheral T-cell lymphoma or cutaneous T-cell lymphoma treated with pralatrexate. Leuk Lymphoma. 2019;60(12):2927–30.CrossRef
56.
Kim SJ, Shin DY, Kim JS, et al. A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas. Ann Oncol. 2016;27(4):712–8.PubMedCrossRef
57.
Kim SJ, Yoon DH, Kang HJ, Kim JS, Park SK, Kim HJ, et al. Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial. Eur J Cancer. 2012;48(17):3223–31.PubMedCrossRef
58.
Lemonnier F, Safar V, de Leval L, et al. Lenalidomide in combination with CHOP in patients with angioimmunoblastic T-cell lymphoma (AITL): final analysis of clinical and molecular data of a phase 2 LYSA study. Blood. 2018;132(Suppl 1):999.CrossRef
59.
Altmann B, Wulf G, Truemper L, et al. Alemtuzumab added to CHOP for treatment of peripheral T-cell lymphoma (PTCL) in previously untreated young and elderly patients: pooled analysis of the international ACT-1/2 phase III trials. Blood. 2018;132(Suppl 1):1622.CrossRef
60.
Advani RH, Ansell SM, Lechowicz MJ, et al. A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial. Br J Haematol. 2016;172(4):535–44.PubMedCrossRef
61.
Dupuis J, Morschhauser F, Ghesquieres H, et al. Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 study. Lancet Haematol. 2015;2(4):e160–5.PubMedCrossRef
62.
•• Horwitz SM, Koch R, Porcu P, et al. Activity of the PI3K-delta,gamma inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma. Blood. 2018;131(8):888–98 This early phase clinical trial of duvelisib demonstrated a high overall response rate and supported the ongoing assessment of duvelisib, a PI3 kinase inhibitor, in an ongoing phase 2 clinical trial. PubMedPubMedCentralCrossRef
63.
•• Horwitz SM, Hamlin PA, Feldman T, et al. Tolerability and response of the novel SYK/JAK inhibitor cerdulatinib in a phase 2a study in relapsed/refractory peripheral t cell lymphoma (PTCL). J Clin Oncol. 2018;36(15_suppl):e19532 This early phase clinical trial of cerdulatinib demosntrated a high overall response rate to cerdulatinib and supports its further investigation in this disease. CrossRef
64.
Lemonnier F, Dupuis J, Sujobert P, Tournillhac O, Cheminant M, Sarkozy C, et al. Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma. Blood. 2018;132(21):2305–9.PubMedCrossRef
65.
Connor OA, Zullo K, Marchi E, et al. Targeting epigenetic operations with HDAC inhibitor and hypomethylating drugs in combination exhibit synergy in preclinical and clinical experiences in drug resistant T-cell lymphoma (TCL): a translational focus on doublet development. Blood. 2015;126(23):1282.CrossRef
66.
• Falchi L, Lue JK, Montanari F, et al. Combined hypomethylating agents (HMA) and histone deacetylase inhibitors (HDACi) exhibit compelling activity in patients with peripheral T-cell lymphoma (PTCL) with high complete response rates in angioimmunoblastic T-cell lymphoma (AITL). Blood. 2018;132(Suppl 1):1002 This early phase clinical trial demonstrated significant activity for overall response rate and complete response rate in angioimmunblastic T-cell lymphoma in the relapsed setting. CrossRef
67.
• Amengual JE, Lichtenstein R, Lue J, et al. A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma. Blood. 2018;131(4):397–407 This early phase clinical trial demonstrated significant activity for overall response rate and complete response rate in peripheral T-cell lymphoma in the relapsed setting. PubMedPubMedCentralCrossRef
68.
Zinzani PL, Bonthapally V, Huebner D, Lutes R, Chi A, Pileri S. Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: peripheral T-cell lymphomas. Crit Rev Oncol Hematol. 2016;99:214–27.PubMedCrossRef
69.
Lesokhin AM, Ansell SM, Armand P, Scott EC, Halwani A, Gutierrez M, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study. J Clin Oncol. 2016;34(23):2698–704.PubMedPubMedCentralCrossRef
70.
Barta SK, Zain J, MacFarlane AW, et al. Phase II study of the PD-1 inhibitor pembrolizumab for the treatment of relapsed or refractory mature T-cell lymphoma. Clin Lymphoma Myeloma Leuk. 2019;19(6):356–364.e353.PubMedCrossRefPubMedCentral
71.
Ratner L, Waldmann TA, Janakiram M, Brammer JE. Rapid progression of adult T-cell leukemia-lymphoma after PD-1 inhibitor therapy. N Engl J Med. 2018;378(20):1947–8.PubMedCrossRef
72.
Ramos CA, Ballard B, Zhang H, Dakhova O, Gee AP, Mei Z, et al. Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. J Clin Invest. 2017;127(9):3462–71.PubMedPubMedCentralCrossRef
73.
Bieling M, Tischer S, Kalinke U, et al. Personalized adoptive immunotherapy for patients with EBV-associated tumors and complications: evaluation of novel naturally processed and presented EBV-derived T-cell epitopes. Oncotarget. 2018;9(4):4737–57.PubMedCrossRef
74.
Ansell SM, Bartlett NL, Chen RW, et al. Investigating safety and preliminary efficacy of AFM13 plus pembrolizumab in patients with relapsed/refractory hodgkin lymphoma after brentuximab vedotin failure. HEMATOL ONCOL. 2019;37(S2):177–8.CrossRef
75.
Sawas A, Chen P, Vlad G, et al. Clinical and biological evaluation of the novel CD30/CD16A tetravalent bispecific antibody (AFM13) in relapsed or refractory CD30-positive lymphoma with cutaneous presentation: a biomarker phase IB/IIA study (NCT03192202). Hematol Oncol. 2019;37(S2):314–6.CrossRef
76.
Damaj G, Gressin R, Bouabdallah K, Cartron G, Choufi B, Gyan E, et al. Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial. J Clin Oncol. 2013;31(1):104–10.PubMedCrossRef
77.
Ogura M, Ishida T, Hatake K, et al. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol. 2014;32(11):1157–63.PubMedCrossRef
78.
Toumishey E, Prasad A, Dueck G, et al. Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma. Cancer. 2015;121(5):716–23.PubMedCrossRef
79.
Dreyling M, Morschhauser F, Bouabdallah K, et al. Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. Ann Oncol. 2017;28(9):2169–78.PubMedPubMedCentralCrossRef
80.
O’Connor OA, Ozcan M, Jacobsen ED, et al. Randomized phase III study of Alisertib or Investigator’s choice (selected single agent) in patients with relapsed or refractory peripheral T-cell lymphoma. J Clin Oncol. 2019;37(8):613–23.PubMedPubMedCentralCrossRef
81.
Witzig T, Sokol L, Kim W, et al. Tipifarnib in relapsed or refractory angioimmunoblastic T-cell lymphoma (AITL) and CXCL12+ peripheral t-cell lymphoma (PTCL): preliminary results from a phase 2 study. Hematol Oncol. 2019;37(S2):64–5.CrossRef
82.
Tan D, Phipps C, Hwang WY, Tan SY, Yeap CH, Chan YH, et al. Panobinostat in combination with bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma: an open-label, multicentre phase 2 trial. Lancet Haematol. 2015;2(8):e326–33.PubMedCrossRef
83.
Pellegrini C, Dodero A, Chiappella A, et al. A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients. J Hematol Oncol. 2016;9:38.PubMedPubMedCentralCrossRef
84.
O’Connor OA, Falchi L, Lue JK, et al. Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multi-center phase I study. Blood. 2019;134(17):1395–1405.PubMedCrossRef
Metadata
Title
Therapy of Peripheral T Cell Lymphoma: Focus on Nodal Subtypes
Authors
Pamela B. Allen
Barbara Pro
Publication date
01-05-2020
Publisher
Springer US
Published in
Current Oncology Reports / Issue 5/2020
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-020-00902-1

Other articles of this Issue 5/2020

Current Oncology Reports 5/2020 Go to the issue

Gastrointestinal Cancers (J Meyer, Section Editor)

Updates on Imaging of Liver Tumors

Gastrointestinal Cancers (J Meyer, Section Editor)

Liver Transplantation for Cholangiocarcinoma: Insights into the Prognosis and the Evolving Indications

Correction

Correction to: The Present and Future of Liquid Biopsies in Non-Small Cell Lung Cancer: Combining Four Biosources for Diagnosis, Prognosis, Prediction, and Disease Monitoring

Palliative Medicine (A Jatoi, Section Editor)

The Physical Consequences of Chemotherapy-Induced Peripheral Neuropathy

Hot Topic

COVID-19 and Cancer: a Comprehensive Review

Lung Cancer (H Borghaei, Section Editor)

Hyperprogressive Disease upon Immune Checkpoint Blockade: Focus on Non–small Cell Lung Cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits